

November 20, 2014



Ceapro Appoints World Renowned Health and Disease Management Expert, William W. Li, M.D. to Board of Directors

EDMONTON, ALBERTA -- (Marketwired) -- 11/20/14 -- [Ceapro Inc. \(TSX VENTURE:CZO\)](#) ("**Ceapro**" or the "**Company**"), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today the Company has appointed international health and disease management expert, William W. Li, M.D., to its Board of Directors.

Dr. Li is the President, Medical Director and Co-founder of the [Angiogenesis Foundation](#), and leads a worldwide revolution in diet and disease prevention based on emerging clinical research and technological advances. Through his work at the Angiogenesis Foundation, he has developed a unique social enterprise model based on international collaborations with leading medical academic centers, biopharmaceutical companies and government agencies, including the National Institutes of Health, National Cancer Institute and the Food and Drug Administration. Dr. Li's expertise extends across numerous medical specialties including oncology, hematology, cardiology, diabetes, ophthalmology, dermatology and wound care along with a diverse category of other disease areas and health conditions.

Glenn Rourke, MBA, Chairman of the Board and Gilles Gagnon, M.Sc., MBA, President and CEO of Ceapro, stated, "We are honored to have a world renowned visionary such as Dr. Li join our Board of Directors. In addition to his own clinical expertise, he also has a unique predictive ability to recognize cutting edge medical breakthroughs well before they are realized. His insight and guidance will be invaluable to Ceapro as we develop our therapeutic technology platform for beta glucan and avenanthramides into the expansive nutraceutical and pharmaceutical markets."

Dr. Li's extensive work has been published in *Science*, *The New England Journal of Medicine*, *Nature Reviews Clinical Oncology*, *The Lancet* and other leading peer-reviewed medical journals. He is a highly sought international lecturer and advisor, and has been recognized by *O Magazine*, *The Atlantic*, *USA Today*, *The New York Times*, *TIME Magazine*, *Wall Street Journal* and *CNN*, as well as the Bill and Melinda Gates Foundation and the Clinton Global Initiative. Additionally, Dr. Li's diet and disease prevention expertise has been featured on "The Doctor Oz Show" television show including his recent [Eat to Defeat Cancer](#) initiative, a healthy eating campaign in over 130 countries.

Dr. Li stated, "It is my great pleasure to join the Ceapro Board of Directors at this important time as the Company expands its natural ingredient product expertise into additional therapeutic indications. Ceapro has leading, proprietary expertise in extracting two essential pharmaceutical grade active ingredients, avenanthramides and beta glucan, which have

respectively anti-inflammatory, anti-aging and cholesterol lowering properties. I believe both of Ceapro's active ingredients have great potential to address unmet consumer needs across a broad spectrum of health and disease."

Dr. Li received his A.B. with honors from Harvard College, and his M.D. from the University of Pittsburgh School of Medicine, Pennsylvania. He completed his clinical training in General Internal Medicine at the Massachusetts General Hospital in Boston. Dr. Li has held appointments on the clinical faculties of Harvard Medical School, Tufts University, and at Dartmouth Medical School. He is an Honorary Fellow of the American College of Wound Care Specialists, and has served as advisor and consultant to leading global public and private companies.

Dr. Li was granted options to purchase 150,000 common shares, each with an exercise price according to TSX-V regulations. Each grant vests in three equal installments, the first of which vests immediately with the second and third instalments vesting on the first and second anniversaries of the date of grant. Each option is exercisable, once vested, for a period of ten years from the date of grant.

About Ceapro Inc.

Ceapro Inc. is a Canadian biotechnology company involved in the development of proprietary extraction technology and the application of this technology to the production of extracts and "active ingredients" from oats and other renewable plant resources. Ceapro adds further value to its extracts by supporting their use in cosmeceutical, nutraceutical, and therapeutics products for humans and animals. The Company has a broad range of expertise in natural product chemistry, microbiology, biochemistry, immunology and process engineering. These skills merge in the fields of active ingredients, biopharmaceuticals and drug-delivery solutions. For more information on Ceapro, please visit the Company's website at www.ceapro.com.

Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

INVESTOR/MEDIA CONTACT:

Jenene Thomas

Jenene Thomas Communications, LLC

Investor Relations and Corporate Communications Advisor

T (US): 908-938-1475

E: jenene@jenenethomascommunications.com

Source: Ceapro Inc.